These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 35956246)

  • 1. New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics.
    Ebata S; Yoshizaki-Ogawa A; Sato S; Yoshizaki A
    J Clin Med; 2022 Aug; 11(15):. PubMed ID: 35956246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
    Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
    Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
    Kuwana M; Allanore Y; Denton CP; Distler JHW; Steen V; Khanna D; Matucci-Cerinic M; Mayes MD; Volkmann ER; Miede C; Gahlemann M; Quaresma M; Alves M; Distler O
    Arthritis Rheumatol; 2022 Mar; 74(3):518-526. PubMed ID: 34514739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research.
    Hoffmann-Vold AM; Brunborg C; Airò P; Ananyeva LP; Czirják L; Guiducci S; Hachulla E; Li M; Mihai C; Riemekasten G; Sfikakis PP; Valentini G; Kowal-Bielecka O; Allanore Y; Distler O;
    Chest; 2023 Mar; 163(3):586-598. PubMed ID: 36244404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline absolute monocyte count predicts lung function decline among patients with systemic sclerosis-associated interstitial lung disease: A post hoc analysis from the focuSSced trial.
    Bernstein EJ; Denton CP; Huang S; Khanna D
    Semin Arthritis Rheum; 2024 Apr; 65():152376. PubMed ID: 38244446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression.
    Khanna D; Maher TM; Volkmann ER; Allanore Y; Smith V; Assassi S; Kreuter M; Hoffmann-Vold AM; Kuwana M; Stock C; Alves M; Sambevski S; Denton CP
    RMD Open; 2023 Feb; 9(1):. PubMed ID: 36796874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis.
    Kreuter M; Del Galdo F; Miede C; Khanna D; Wuyts WA; Hummers LK; Alves M; Schoof N; Stock C; Allanore Y
    Arthritis Res Ther; 2022 Jan; 24(1):19. PubMed ID: 35012623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects.
    Maher TM; Bourdin A; Volkmann ER; Vettori S; Distler JHW; Alves M; Stock C; Distler O
    Respir Res; 2022 Jul; 23(1):178. PubMed ID: 35790961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Distler O; Highland KB; Gahlemann M; Azuma A; Fischer A; Mayes MD; Raghu G; Sauter W; Girard M; Alves M; Clerisme-Beaty E; Stowasser S; Tetzlaff K; Kuwana M; Maher TM;
    N Engl J Med; 2019 Jun; 380(26):2518-2528. PubMed ID: 31112379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease.
    Allanore Y; Khanna D; Smith V; Aringer M; Hoffmann-Vold AM; Kuwana M; Merkel PA; Stock C; Sambevski S; Denton CP;
    Rheumatology (Oxford); 2024 Mar; 63(3):639-647. PubMed ID: 37294870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial.
    Khanna D; Lin CJF; Furst DE; Wagner B; Zucchetto M; Raghu G; Martinez FJ; Goldin J; Siegel J; Denton CP
    Am J Respir Crit Care Med; 2022 Mar; 205(6):674-684. PubMed ID: 34851799
    [No Abstract]   [Full Text] [Related]  

  • 13. [Antifibrotic therapy - new approvals for non-IPF interstitial lung diseases].
    Markart P; Drakopanagiotakis F; Wygrecka M
    Dtsch Med Wochenschr; 2021 Feb; 146(3):181-184. PubMed ID: 33513653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.
    Yamasaki Y; Kuwana M
    Expert Rev Clin Immunol; 2020 Jun; 16(6):547-560. PubMed ID: 32506975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Khanna D; Lin CJF; Furst DE; Goldin J; Kim G; Kuwana M; Allanore Y; Matucci-Cerinic M; Distler O; Shima Y; van Laar JM; Spotswood H; Wagner B; Siegel J; Jahreis A; Denton CP;
    Lancet Respir Med; 2020 Oct; 8(10):963-974. PubMed ID: 32866440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial.
    Kuwana M; Ogura T; Makino S; Homma S; Kondoh Y; Saito A; Ugai H; Gahlemann M; Takehara K; Azuma A
    Mod Rheumatol; 2021 Jan; 31(1):141-150. PubMed ID: 32243207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease.
    Atanelishvili I; Akter T; Noguchi A; Vuyiv O; Wollin L; Silver RM; Bogatkevich GS
    Clin Exp Rheumatol; 2019; 37 Suppl 119(4):115-124. PubMed ID: 31573469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease.
    Wollin L; Trinh-Minh T; Zhang Y; Distler JHW
    Clin Exp Rheumatol; 2021; 39 Suppl 131(4):134-141. PubMed ID: 33886452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
    J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).
    Distler O; Brown KK; Distler JHW; Assassi S; Maher TM; Cottin V; Varga J; Coeck C; Gahlemann M; Sauter W; Schmidt H; Highland KB;
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):75-81. PubMed ID: 28664834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.